All > Her 2 Positive Breast Cancer > Breast Cancer

Angiomammography for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Breast CancerAngiomammography - DiagnosticTest
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial is looking at whether a less expensive and more readily available diagnostic modality, namely CESM, is as effective as MRI in predicting the response of a malignant breast tumor to neoadjuvant chemotherapy and the chances of achieving a pCR.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Perflutren Lipid Microcpheres
1
Perflubutane Microbubble
1
Eflapegrastim

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.

Day 21
Number of patients with a pCR accoreding to angiomammography, based on a 50% reduction in lesion size at angiomammography
Prediction of pCR using angiomammography, based on a 50% reduction in lesion size at angiomammography

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Perflutren Lipid Microcpheres
1
Perflubutane Microbubble
1
Eflapegrastim

Trial Design

1 Treatment Group

Neoadjuvant chemotherapy
1 of 1

Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: Angiomammography · No Placebo Group · N/A

Neoadjuvant chemotherapy
DiagnosticTest
Experimental Group · 1 Intervention: Angiomammography · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.

Who is running the clinical trial?

CHU de Quebec-Universite LavalLead Sponsor
152 Previous Clinical Trials
101,367 Total Patients Enrolled
3 Trials studying Breast Cancer
1,031 Patients Enrolled for Breast Cancer

Eligibility Criteria

Age 18+ · Female Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Neoadjuvant chemotherapy with or without concomitant targeted therapy.
You are female aged 18 and over.\n
You have histologically proven breast cancer by large gauge needle.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top